Sotrovimab: Difference between revisions
(Created page with "==Administration== *Type: *Dosage Forms: *Routes of Administration: *Common Trade Names: ==Adult Dosing== ==Pediatric Dosing== ==Special Populations== ===Drug pregnan...") |
No edit summary |
||
| Line 6: | Line 6: | ||
==Adult Dosing== | ==Adult Dosing== | ||
===[[COVID]]=== | |||
* 500 mg IV over 30 min, observe for 1 hour after | |||
| Line 45: | Line 47: | ||
==Comments== | ==Comments== | ||
* | *Newer, very limited supply | ||
==See Also== | ==See Also== | ||
Latest revision as of 20:45, 18 January 2022
Administration
- Type:
- Dosage Forms:
- Routes of Administration:
- Common Trade Names:
Adult Dosing
COVID
- 500 mg IV over 30 min, observe for 1 hour after
Pediatric Dosing
Special Populations
Pregnancy Rating
Lactation risk
Renal Dosing
- Adult:
- Pediatric:
Hepatic Dosing
- Adult:
- Pediatric:
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
Common
Pharmacology
- Half-life:
- Metabolism:
- Excretion:
Mechanism of Action
Comments
- Newer, very limited supply